NovoCure (NVCR) Competitors

NovoCure (NASDAQ:NVCR) and Glaukos (NYSE:GKOS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

Does the media prefer NVCR or GKOS?

In the previous week, Glaukos had 11 more articles in the media than NovoCure. MarketBeat recorded 16 mentions for Glaukos and 5 mentions for NovoCure. Glaukos' average media sentiment score of 1.50 beat NovoCure's score of 0.62 indicating that Glaukos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	1 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has more volatility and risk, NVCR or GKOS?

NovoCure has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, Glaukos has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500.

Is NVCR or GKOS more profitable?

Glaukos has a net margin of -21.43% compared to NovoCure's net margin of -27.13%. Glaukos' return on equity of -8.59% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-27.13%	-47.74%	-13.79%
Glaukos	-21.43%	-8.59%	-6.61%

Do analysts rate NVCR or GKOS?

NovoCure presently has a consensus target price of $28.79, suggesting a potential upside of 131.58%. Glaukos has a consensus target price of $127.42, suggesting a potential upside of 35.25%. Given NovoCure's higher probable upside, research analysts clearly believe NovoCure is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Glaukos	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

Do institutionals & insiders hold more shares of NVCR or GKOS?

84.6% of NovoCure shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 5.5% of NovoCure shares are owned by insiders. Comparatively, 5.8% of Glaukos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Which has higher valuation & earnings, NVCR or GKOS?

Glaukos has lower revenue, but higher earnings than NovoCure. Glaukos is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$605.22M	2.30	-$168.63M	-$1.56	-7.97
Glaukos	$383.48M	14.09	-$146.37M	-$1.65	-57.10

Summary

Glaukos beats NovoCure on 13 of the 17 factors compared between the two stocks.